Cargando…
Translating tolerogenic therapies to the clinic – where do we stand?
Manipulation of the immune system to prevent the development of a specific immune response is an ideal strategy to improve outcomes after transplantation. A number of experimental techniques exploiting central and peripheral tolerance mechanisms have demonstrated success, leading to the first early...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Research Foundation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3422982/ https://www.ncbi.nlm.nih.gov/pubmed/22934094 http://dx.doi.org/10.3389/fimmu.2012.00254 |
_version_ | 1782241068309282816 |
---|---|
author | Issa, Fadi Wood, Kathryn J. |
author_facet | Issa, Fadi Wood, Kathryn J. |
author_sort | Issa, Fadi |
collection | PubMed |
description | Manipulation of the immune system to prevent the development of a specific immune response is an ideal strategy to improve outcomes after transplantation. A number of experimental techniques exploiting central and peripheral tolerance mechanisms have demonstrated success, leading to the first early phase clinical trials for tolerance induction. The first major strategy centers on the facilitation of donor-cell mixed chimerism in the transplant recipient with the use of bone marrow or hematopoietic stem cell transplantation. The second strategy, utilizing peripheral regulatory mechanisms, focuses on cellular therapy with regulatory T cells. This review examines the key studies and novel research directions in the field of immunological tolerance. |
format | Online Article Text |
id | pubmed-3422982 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Frontiers Research Foundation |
record_format | MEDLINE/PubMed |
spelling | pubmed-34229822012-08-29 Translating tolerogenic therapies to the clinic – where do we stand? Issa, Fadi Wood, Kathryn J. Front Immunol Immunology Manipulation of the immune system to prevent the development of a specific immune response is an ideal strategy to improve outcomes after transplantation. A number of experimental techniques exploiting central and peripheral tolerance mechanisms have demonstrated success, leading to the first early phase clinical trials for tolerance induction. The first major strategy centers on the facilitation of donor-cell mixed chimerism in the transplant recipient with the use of bone marrow or hematopoietic stem cell transplantation. The second strategy, utilizing peripheral regulatory mechanisms, focuses on cellular therapy with regulatory T cells. This review examines the key studies and novel research directions in the field of immunological tolerance. Frontiers Research Foundation 2012-08-20 /pmc/articles/PMC3422982/ /pubmed/22934094 http://dx.doi.org/10.3389/fimmu.2012.00254 Text en Copyright © Issa and Wood. http://www.frontiersin.org/licenseagreement This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) , which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc. |
spellingShingle | Immunology Issa, Fadi Wood, Kathryn J. Translating tolerogenic therapies to the clinic – where do we stand? |
title | Translating tolerogenic therapies to the clinic – where do we stand? |
title_full | Translating tolerogenic therapies to the clinic – where do we stand? |
title_fullStr | Translating tolerogenic therapies to the clinic – where do we stand? |
title_full_unstemmed | Translating tolerogenic therapies to the clinic – where do we stand? |
title_short | Translating tolerogenic therapies to the clinic – where do we stand? |
title_sort | translating tolerogenic therapies to the clinic – where do we stand? |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3422982/ https://www.ncbi.nlm.nih.gov/pubmed/22934094 http://dx.doi.org/10.3389/fimmu.2012.00254 |
work_keys_str_mv | AT issafadi translatingtolerogenictherapiestotheclinicwheredowestand AT woodkathrynj translatingtolerogenictherapiestotheclinicwheredowestand |